State of the Science Summit on Genitourinary Cancers | Conference

Assessing Long-Anticipated Treatment Advances in Metastatic Urothelial Cancer

January 2nd 2020

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

December 4th 2019

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Dr. Beckermann on Sequencing Strategies in mRCC

December 4th 2019

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Expert Shares Insight on Recent Prostate Cancer Developments

November 27th 2019

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

November 26th 2019

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer

November 22nd 2019

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

November 20th 2019

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Selecting Among AR-Directed Agents in Nonmetastatic CRPC

November 16th 2019

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Tracers Increase PET Imaging Sensitivity in Prostate Cancer

August 27th 2019

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.

x